Format

Send to

Choose Destination
Surg Oncol Clin N Am. 2013 Oct;22(4):705-46. doi: 10.1016/j.soc.2013.06.011. Epub 2013 Aug 6.

Targeting the NF-κB pathway in cancer therapy.

Author information

1
Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.

Abstract

Most NF-κB inhibitors target the IKK complex, IκB proteins, or NF-κB transcription factors. The most promising classes of inhibitors include antioxidants, antiinflammatory compounds, natural compounds, statins, proteasome inhibitors, IKKβ inhibitors, biologics, gene therapy, and RNA interference. Targeting NF-κB is limited by intrinsic pathway complexity, cross-talk with other pathways, a lack of biomarkers, poor drug specificity, drug resistance, and difficulty with drug delivery. Future NF-κB targeting will be improved through better understanding of the pathway, more specific inhibitors, and multimodality therapies.

KEYWORDS:

Apoptosis; Chemoresistance; IKK inhibitor; NF-κB inhibitor; Radioresistance; Targeting NF-κB

PMID:
24012396
DOI:
10.1016/j.soc.2013.06.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center